A range of targeted therapies is currently being evaluated in clinical trials for specific patient populations, including BRAF mutant CRC therapies utilizing combinations such as encorafenib and cetuximab, HER2-targeted therapies (trastuzumab and pertuzumab) for HER2-positive CRC, and KRAS G12C inhibitors, such as sotorasib [161,162]. This evidence concerns the gene BRAF and colorectal carcinoma.